Skip to main content
. 2018 Nov 5;128(12):5479–5488. doi: 10.1172/JCI120156

Figure 6. AZD9150 leads to decreased leukemic engraftment in primary MDS/AML xenografts.

Figure 6

(A) MDS patient-derived xenografts (n = 3) were prepared by transplantation of peripheral blood or BM mononuclear cells (MNCs) into irradiated NSG mice. After confirmation of engraftment by serial bone marrow samples, the cohort was split and treated with either drug at a dose of 50 mg/kg or control oligonucleotide at the same dose for 4 weeks. (B) A low-risk MDS patient analyzed after 4 weeks of treatment shows improved engraftment in the control-treated mice but a loss of graft in AZD9150-treated mice, as demonstrated by the human CD45 antibody. (C) A high-risk MDS patient with similarly improved graft in control compared with AZD9150-treated mice. *P < 0.05 by t test. Fold change of human CD45 in drug-treated mice was greatly reduced in comparison with control (n = 3).